Use of test
Gene fusions involving the BCL6 gene at 3q27 can occur in B-cell non-Hodgkin lymphomas (B-NHL), particularly diffuse large B-cell lymphoma (DLBCL). BCL6 gene fusions are also seen in patients with follicular lymphoma or marginal zone lymphoma. These gene fusions have diagnostic and prognostic implications.
Presence of a BCL6 gene fusion can be useful in diagnosing and sub-classifying B-NHLs. It can also indicate prognosis in B-cell lymphoma with features intermediate between DLBCL and Burkitt lymphoma, in association with BCL2 and MYC gene fusions (see Multiple hit lymphoma FISH).
This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.
Fluorescent in situ hybridisation (FISH) analysis, using probes to identify fusion of BCL6 with a partner gene. The breakpoints involved in these fusions can be variable, and in some cases certain variants will not be detected by the probe.
Requesting the test
This test is usually requested by a haematologist or oncologist.
0.5 mL bone marrow in transport media, or formalin-fixed, paraffin embedded tissue (FFPE).
To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.
We recommend that the patient or another adult check the labelling of request forms and sample tubes.
5 business days.
Up to $255.
If more information is required, the requesting clinician can call our laboratory on (07) 3377 8573.
This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.